Ovarian Cancer News and Research RSS Feed - Ovarian Cancer News and Research Twitter

Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research will recognize Philip S. Low, PhD, with the ninth annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. [More]
CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China. [More]
Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers. [More]
DNA samples collected from tampons may help detect endometrial cancer

DNA samples collected from tampons may help detect endometrial cancer

Researchers at Mayo Clinic have shown that it is possible to detect endometrial cancer using tumor DNA picked up by ordinary tampons. The new approach specifically examines DNA samples from vaginal secretions for the presence of chemical "off" switches — known as methylation — that can disable genes that normally keep cancer in check. [More]
MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, today announced top-line data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). [More]
Promising new treatment for hereditary breast/ovarian cancer

Promising new treatment for hereditary breast/ovarian cancer

European scientists recently discovered a novel therapy to treat a subgroup of patients with hereditary breast/ovarian cancer. Both the EU and the US have approved an accelerated procedure to market this promising new treatment with few side effects. [More]
Chemical found in stinging nettles and ants could improve cancer drug

Chemical found in stinging nettles and ants could improve cancer drug

A cancer drug could be made 50 times more effective by a chemical found in stinging nettles and ants, new research finds. [More]
PARP inhibitors can be effective in broader group of patients

PARP inhibitors can be effective in broader group of patients

A pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumours with another type of genetic fault, a new study suggests. [More]
ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM). [More]
Hormone therapy does not safeguard post-menopausal women against cardiovascular disease

Hormone therapy does not safeguard post-menopausal women against cardiovascular disease

New evidence published today in the Cochrane Library shows that hormone replacement therapy does not protect post-menopausal women against cardiovascular disease, and may even cause an increased risk of stroke. [More]
Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences. [More]
VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has initiated a pilot study to assess the feasibility of VolitionRx's proprietary NuQ assays in detecting prostate cancer. [More]
FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of primary peritoneal cancers. [More]

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of cancer of the fallopian tube. [More]
Researchers outline personalized surgical approach to ovarian cancer

Researchers outline personalized surgical approach to ovarian cancer

A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor - a milestone strongly tied to improved survival. [More]
Study finds racial disparities among children with Crohn's disease

Study finds racial disparities among children with Crohn's disease

A study published recently in the IBD Journal found significant differences in hospital readmissions, medication usage, and both medical and surgical complications of children with Crohn's disease related to race. In the study, black children had a 1.5 times higher frequency of hospital readmissions because of Crohn's disease compared to white children. [More]
New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months. [More]
Researchers find that new targeted drugs can attack weak spots in cancer cells

Researchers find that new targeted drugs can attack weak spots in cancer cells

Scientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs. [More]
Serous ovarian cancer is more deadly, shows Cancer Research UK study

Serous ovarian cancer is more deadly, shows Cancer Research UK study

THE most common type of ovarian cancer is more deadly if it consists of a patchwork of different groups of cells, according to a Cancer Research UK study published today (Tuesday) in PLOS Medicine. [More]
Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Our research into gynaecological oncology focuses around understanding mechanisms of how genes are regulated or how they become dysregulated in a disease; and also the effects that has on the surface of the endometrium and also the function of the ovaries... [More]
Advertisement
Advertisement